In a background of high genomic HIV-1 variability with a predominance of CRF11_cpx and CRF22_01A1, we have studied the emergence of resistance mutations in isolates from Central African patients at failure of d4T-AZT/3TC/NVP-EFV plus two at failure of a PI-including regimen; the resistance mutations observed are those which are expected on HIV-1 subtype B.
Get full access to this article
View all access options for this article.
References
1.
MassangaM, NdoyoJ, HuDJet al.A highly heterogeneous HIV-1 epidemic in the Central African Republic. Emerg Infect Dis, 1996; 2:222–224.
2.
Müller–TrutwinMC, ChaixML, LetourneurFet al.Increase of HIV-1 subtype A in Central African Republic. J Acquir Immune Defic Syndr, 1999; 21:164–171.
3.
MontavonC, VergneL, BourgeoisAet al.Identification of a new circulating recombinant form of HIV type 1, CRF11-cpx, involving subtypes A, G, J, CRF01-AE, in Central Africa. AIDS Res Hum Retroviruses, 2002; 18:231–236.
4.
BégaudE, FeindirongaiG, VersmissePet al.Broad spectrum of coreceptor usage, rapid disease progression in HIV-1-infected individuals from Central African Republic. AIDS Res Hum Retroviruses, 2003; 19:551–560.
5.
MarechalV, JauvinV, SelekonBet al.Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: A 2005 study. AIDS Res Hum Retroviruses, 2006; 22:1036–1044.
6.
KantorR. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis, 2006; 19:594–606.
7.
BrennerBG. Resistance, viral subtypes: How important are the differences and why do they occur?Curr Opin HIV AIDS, 2007; 2:94–102.
8.
Martínez–CajasJL, Pant–PaiN, KleinMB, WainbergMA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence. AIDS Rev, 2008; 10:212–223.
